BenevolentAI Investor Conference Presentation Deck
Key investment highlights
Pioneer & leader in Al-augmented drug discovery, enabled by the Benevolent Platform™
Benevolent
Clear, growing market demand from Biopharma to leverage Al in drug discovery
and increase probability of success
Business model offers multiple routes for revenue generation and value
creation
Leading End-to-End Drug Discovery solutions, validated through industry
collaborations with AstraZeneca and Merck
High potential Preclinical & Clinical Development Pipeline with strategic
optionality delivering financial upside; lead asset BEN-8744 in Phase I
New expansion opportunity through suite of Knowledge Exploration tools that
leverage bio-specific natural language processing and large language models
Benevolent
Platform
Market demand
for Al in drug
discovery
End-to-End Drug
Discovery
External
collaborations
Internal
pipeline
Preclinical &
Clinical
Development
Pipeline
BEN-8744
BEN-28010
BEN-34712
Parkinson's
Fibrosis
New Knowledge
Exploration tools
P
Knowledge
Exploration
Tools
Merck
AstraZeneca
BenAl-Q
BenAl Research
Assistant
Benevolent (11View entire presentation